LI-COR Biosciences Inc.

Former executives from the autologous chimeric antigen receptor T-cell (CAR-T) therapy developer Juno Therapeutics Inc. , following the company's $9bn acquisition by Celgene Corp. last year, have l

Rakuten Aspyrian Inc. has raised $150m in Series C venture capital to fund a Phase III clinical trial that it intends to start before the end of this year to test its laser-activated antibody conjuga

A year after Flagship Pioneering updated its name to reflect the firm's investments in innovation and company creation, and revealed a new $285m special opportunities fund, it announced on Dec. 20 tha

Perkin-Elmer's Applied Biosystems division makes the DNA sequencers that make genomics go. But has most of the value enabled by Perkin-Elmer instruments been realized by other companies' investors? No